Despite today's stormy session on the Tel Aviv Stock Exchange (TASE), sources inform ''Globes'' that biotechnology company Aposense Ltd. raised the NIS 60 million planned in the institutional tender of its IPO. The amount is 80% of the total amount the company plans to raise.
It remains to be seen what will be the minimum price Aposense will accept in the institutional tender. The company will hold the public tender of the IPO next week.
Prior to the IPO, Aposense raised $3 million from Pontifax Fund and Ziegler Meditech Equity Partners. Leumi Partners Ltd., one of the underwriters, has committed to invest NIS 18.75 million in the company.
Aposense has developed a molecule that targets cells undergoing the process of apoptosis (programmed cell death), on the basis of which it developing clinical imaging and targeted therapy products.
Published by Globes [online], Israel business news - www.globes-online.com - on May 31, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010